Literature DB >> 11834970

Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1.

Helen Donners, Betty Willems, Els Beirnaert, Robert Colebunders, David Davis, Guido van der Groen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11834970     DOI： 10.1097/00002030-200202150-00030

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  10 in total

1.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

2.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

3.  Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Authors:  Elin S Gray; Maphuti C Madiga; Penny L Moore; Koleka Mlisana; Salim S Abdool Karim; James M Binley; George M Shaw; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

4.  Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency.

Authors:  Sandra D Taylor; Steven R Leib; Wuwei Wu; Robert Nelson; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

5.  Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Authors:  Amandeep K Dhillon; Helen Donners; Ralph Pantophlet; Welkin E Johnson; Julie M Decker; George M Shaw; Fang-Hua Lee; Douglas D Richman; Robert W Doms; Guido Vanham; Dennis R Burton
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

6.  A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120.

Authors:  Rena D Astronomo; Hing-Ken Lee; Christopher N Scanlan; Ralph Pantophlet; Cheng-Yuan Huang; Ian A Wilson; Ola Blixt; Raymond A Dwek; Chi-Huey Wong; Dennis R Burton
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

7.  Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Authors:  Elin S Gray; Natasha Taylor; Diane Wycuff; Penny L Moore; Georgia D Tomaras; Constantinos Kurt Wibmer; Adrian Puren; Allan DeCamp; Peter B Gilbert; Blake Wood; David C Montefiori; James M Binley; George M Shaw; Barton F Haynes; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

8.  Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.

Authors:  Rajesh Ringe; Madhuri Thakar; Jayanta Bhattacharya
Journal:  Retrovirology       Date:  2010-09-22       Impact factor: 4.602

9.  Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.

Authors:  Gerald V Quinnan; Pengfei Zhang; Ming Dong; Hong Chen; Yan-Ru Feng; Mark Lewis; Christopher C Broder
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

10.  Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.

Authors:  Yabo OuYang; Jianping Sun; Yang Huang; Lu Lu; Weisi Xu; Xintao Hu; Kunxue Hong; Shibo Jiang; Yiming Shao; Liying Ma
Journal:  Virol J       Date:  2013-01-05       Impact factor: 4.099
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.